The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

The novel design of AtaCor's Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies ...

AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.

Leqembi ® Iqlik™, a subcutaneous (SC) formulation of lecanemab, is now available as a maintenance dosing regimen for the treatment of Alzheimer disease in patients with mild cognitive impairment or ...